Medicus Pharma Ltd. has submitted an Orphan Drug Designation (ODD) application to the FDA for SkinJect® (D-MNA), targeting basal cell carcinoma (BCC) in patients with Gorlin Syndrome. This rare genetic disorder leads to the formation of multiple skin cancers, presenting a significant clinical challenge due to the lack of FDA-approved therapies specifically for this indication. Current treatment options primarily involve surgical excisions, which can result in cumulative morbidity and disfigurement. The ODD submission marks a strategic move to address this high unmet need with a novel therapeutic approach.

SkinJect® utilizes a dissolvable microneedle array for localized delivery of doxorubicin directly into BCC lesions, allowing for high local concentrations with minimal systemic exposure. This mechanism not only facilitates direct cytotoxic effects on tumor cells but also induces immunogenic cell death, potentially activating local immune responses. Early Phase 1 and Phase 2 studies have shown a favorable safety profile and evidence of clinical clearance in treated lesions, supporting the rationale for expanding the SkinJect program into this orphan indication.

The implications of this ODD submission are significant for the field. It positions Medicus to leverage the regulatory advantages associated with orphan drug status, including 7 years of market exclusivity and enhanced FDA interactions. This strategic expansion not only differentiates SkinJect as a repeatable, non-surgical treatment option but also enhances its attractiveness for potential partnerships and out-licensing opportunities. As the landscape of therapeutic development for rare diseases evolves, this initiative could catalyze further innovations in localized cancer therapies and reshape treatment paradigms for patients with Gorlin Syndrome.

Source: globenewswire.com